Intercept Pharma (ICPT) Announces New Data Showing Potential

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Austria , Vienna , Wien , Vaclav Hejda , M Michelle Berrey , Frederik Nevens , Nareg Sagherian , Antonio Civitarese , Cheng Zou , Lynda Szczech , Alexandre Louvet , Karen Preble , Linkedin , Intercept Pharmaceuticals Inc , Nasdaq , Research Development , Company On Twitter , Warfarinthe International Normalized Ratio , Global Corporate Communications , Wall Street , European Association , Chief Medical Officer , Planned Interim Analysis , Active Controlled Trial Evaluating , Obeticholic Acid , Serum Biomarkers , Primary Biliary , Bezafibrate Fixed Dose Combinationintercept , Important Safety Information , Primary Biliary Cholangitisprimary , Acid Binding Resinsbile , International Normalized Ratio , Narrow Therapeutic Indexobeticholic , Bile Salt Efflux Pumpavoid , Full Prescribing Information , Intercept Pharmaceuticals , Executive Director , Global Investor , Global Corporate ,